Program - Society of Toxicology

44 th Annual Meeting
and ToxExpo
Program Description
#1336 10:10 DEVELOPMENT OF PHYSIOLOGICALLY
BASED PHARMACOKINETIC AND
PHARMACODYNAMIC MODELS TO
DETERMINE DOSIMETRY, DYNAMIC
RESPONSE, AND TO ASSESS RISK FOLLOWING
EXPOSURE TO ORGANOPHOSPHORUS
INSECTICIDES. C. Timchalk and T. S. Poet. Pacific
Northwest National Laboratory, Richland, WA.
#1337 10:40 PESTICIDE NEUROTOXICITY IN ADULTS:
IMPLICATIONS FOR PESTICIDE SAFETY
TESTING AND PUBLIC HEALTH. W. K. Boyes.
EPA, Research Triangle Park, NC.
Wednesday Morning, March 9
8:30 AM to 11:30 AM
La Louisiane Ballroom B
WORKSHOP SESSION: CURRENT REGULATORY AND SCIENTIFIC
VIEWS REGARDING CHEMICAL HAZARDS TO CHILDREN
Chairperson(s): Daland Juberg, Dow AgroSciences, LLC, Indianapolis, IN
and Dennis Paustenbach, ChemRisk, San Francisco, CA.
Endorsed by:
Ethical Legal and Social Issues SS
Regulatory and Safety Evaluation SS
Reproductive and Development SS
Risk Assessment SS*
#1341 9:30 EVALUATION OF CHILDHOOD EXPOSURES TO
INDUSTRIAL CHEMICALS THROUGH VCCEP.
P. R. Williams. ChemRisk, Boulder, CO. Sponsor: D.
Paustenbach.
#1342 10:00 EVALUATION AND PREDICTION OF
DOSIMETRY IN CHILDREN: EMPIRICAL AND
MECHANISTIC APPROACHES. A. M. Jarabek.
U.S. EPA Visiting Scientist, CIIT Centers for Health
Research, Research Triangle Park, NC.
#1343 10:30 DIFFERENTIAL SENSITIVITY OF CHILDREN
AND ADULTS TO CHEMICAL TOXICITY AND
THE USE OF UNCERTAINTY FACTORS IN
REGULATING RISKS. G. Charnley 3 , M. L. Dourson 1
and R. Scheuplein 2 . 1 Toxicology Excellence for Risk
Assessment (TERA), Cincinnati, OH, 2 Keller and
Heckman, Stafford, VA and 3 HealthRisk Strategies,
Washington.
#1344 11:00 AN EVALUATION OF ENVIRONMENTAL
HEALTH TRENDS AMONG CHILDREN BASED
ON MEDICAL AND SCIENTIFIC EVIDENCE. D.
A. Goldstein. A2NE, Monsanto Company, St. Louis,
MO. Sponsor: P. Williams.
Wednesday Morning, March 9
8:30 AM to 11:30 AM
Room 207
The evaluation of the health of children, specifically the estimated risk due to
environmental chemical exposures, continues to receive increasing regulatory
attention. It has resulted in decision-making that has scientific, policy, and
public health impacts. At the center of this discussion is whether children are
uniquely susceptible and whether current regulatory approaches are protective
of children. This workshop will discuss ongoing initiatives by the EPA and CDC
aimed at characterizing children’s exposures and evaluating biomonitoring data.
Other parameters that are influential in predicting susceptibility, namely, pharmacokinetics
and pharmacodynamics, will also be addressed. The use of
uncertainty factors in setting environmental criteria and estimating safe doses
will be discussed and a case study from the VCCEP program will be presented.
A view from the medical community, frequently the first responders to questions
and concerns over children’s health, will be offered. The scientific
questions about whether children are significantly more susceptible to toxicants
and the current regulatory response to this concern (e.g., FQPA, testing requirements,
basic research, cancer risk assessment guidelines) are the focus of this
workshop. An anticipated outcome is the identification of those areas of
research that will give the toxicology community the opportunity to be a central
figure in properly addressing this important public health question.
#1338 8:30 CURRENT REGULATORY AND SCIENTIFIC
VIEWS REGARDING CHEMICAL HAZARDS TO
CHILDREN. D. R. Juberg 1 and D. J. Paustenbach 2 .
1 Regulatory Laboratories, Dow AgroSciences,
Indianapolis, IN and 2 ChemRisk, San Francisco, CA.
#1339 8:40 OVERVIEW OF U.S. EPA RESEARCH
ACTIVITIES AIMED AT CHARACTERIZING
CHILDREN’S EXPOSURES. E. A. Cohen Hubal.
U.S. EPA, Research Triangle Park, NC. Sponsor: D.
Juberg.
#1340 9:00 USING CDC BIOMONITORING DATA FOR
ASSESSING CHILDRENS’ EXPOSURES TO
ENVITONMENTAL CHEMICALS. L. L. Needham.
NCEH, CDC, Atlanta, GA. Sponsor: P. Williams.
WORKSHOP SESSION: TOXICOLOGIC EVALUATION OF INHALED
VACCINES
Chairperson(s): Matthew Reed, Lovelace Respiratory Research Instisute,
Albuquerque, NM and Robert House, Dynport Vaccine Company, Frederick,
MD.
Endorsed by:
Immunotoxicology SS
Inhalation SS*
Regulatory and Safety Evaluation SS
Mucosal and systemic immunity stimulated by aerosolized vaccines have been
recognized as effective pathways for preventative immunizations and therapies
for pathogens and diseases ranging from flu (e.g., FluMist) to measles (World
Health Organization) to asthma. Likewise, in the face of an ever-present risk of
aerosol delivery of chemical and biological agents, inhaled vaccines make sense
by stimulating immunity at the portal of pathogen/ chemical entry. However,
several toxicological hurdles exist for those challenged with developing or regulating
vaccines, especially those designed for administration to the respiratory
tract. General toxicological assessment as are required for all vaccine subtypes
are necessary as well as special considerations including safety pharmacology.
Adjuvant type and possible transport to the brain via the olfactory pathway are
of concern as well. This symposium will bring together experts in the field of
inhaled therapeutics and vaccine development, to give insight into the required
and perceived toxicology of aerosolized vaccines.
#1345 8:30 TOXICOLOGIC EVALUATION OF INHALED
VACCINES. M. Reed. Toxicology, Lovelace
Respiratory Research Institute, Albuquerque, NM.
#1346 8:45 AIRWAY DRUG DELIVERY OPTIONS FOR
INHALED BIOLOGICS AND VACCINES. C. Leach.
Preclinical Development, Lovelace Respiratory
Research Institute, Albuquerque, NM.
WEDNESDAY
up-to-date information at www.toxicology.org 153